^
    2d
    Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial (clinicaltrials.gov)
    P2, N=100, Recruiting, Northwestern University | Not yet recruiting --> Recruiting | Initiation date: Mar 2026 --> Dec 2025
    Enrollment open • Trial initiation date
    2d
    CPI: Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy. (clinicaltrials.gov)
    P4, N=110, Not yet recruiting, Centre Antoine Lacassagne
    New P4 trial
    |
    Keytruda (pembrolizumab)
    2d
    ROMA LA-OPSCC2: Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2 (clinicaltrials.gov)
    P=N/A, N=30, Completed, University Health Network, Toronto | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Sep 2025 | Trial primary completion date: Jan 2026 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    5d
    RADIO-PBM: Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, Centre Paul Strauss | Trial completion date: May 2026 --> Nov 2029 | Trial primary completion date: May 2026 --> Nov 2029
    Trial completion date • Trial primary completion date
    5d
    A Study of Neurocognitive Tests and Questionnaires for People With Head and Neck Cancer Who Are Undergoing Radiation Therapy (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open
    6d
    Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, ImmunityBio, Inc.
    New P2 trial
    |
    Avastin (bevacizumab) • cisplatin • albumin-bound paclitaxel • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    6d
    Detection of human papillomavirus infection in oral mucosal diseases: A single-center study. (PubMed, JADA Found Sci)
    The highest rate of HPV infection was in male patients, patients with OL and OLP, and conditions affecting the buccal mucosa. Larger studies are needed to elucidate the role of HPV in the development of these conditions.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    6d
    RADIAN: Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=34, Active, not recruiting, Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2027 --> Mar 2027
    Enrollment closed • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    7d
    Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=39, Recruiting, National Cancer Institute (NCI) | Initiation date: Jun 2026 --> Feb 2027 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date • Tumor mutational burden
    |
    camonsertib (RP-3500)
    7d
    Tumor immune microenvironment predicts recurrence after radiotherapy in oropharyngeal squamous cell carcinoma. (PubMed, Radiother Oncol)
    This exploratory study highlights the prognostic significance of a robust lymphocyte-rich TIME and introduces a clinically relevant 14-gene immune signature that outperforms traditional markers in predicting recurrence in OPSCC. These results suggest that integrating immune gene signatures into routine clinical practice could refine risk stratification and guide personalized therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3)
    |
    nCounter® PanCancer Immune Profiling Panel
    |
    Erbitux (cetuximab) • cisplatin
    7d
    SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
    P2, N=798, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: May 2027 --> May 2026
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    PD-L1 overexpression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    8d
    Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer (clinicaltrials.gov)
    P1, N=43, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027
    Trial completion date
    |
    cisplatin • berzosertib (M6620)